Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach.

Cancers (Basel) · 2022 · PMC9454486 · PMID 36077693

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp = 0.0000006actually significant

One month after the therapy shift (T3), we detected a highly significant decrease in the BRAF p.V600E and MEK1 p.P124L MAFs ( p = 0.0000006 and p = 0.0005, respectively).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.